康辰藥業(603590.SH)擬定增募資不超3億元 由實控人之一王錫娟認購
格隆匯 3 月 1日丨康辰藥業(603590.SH)披露2021年度非公開發行A股股票預案,擬非公開發行預計募集資金總額不超過3億元(含本數),發行數量不超過1072.1944萬股(含本數),未超過本次發行前公司總股本的30%,即未超過4800萬股。本次非公開發行股票的數量以中國證監會最終核准發行的股票數量為準。扣除發行費用後擬全部用於KC1036創新藥物研發項目。
此次發行為面向特定對象的非公開發行,發行對象為公司實際控制人之一王錫娟。前述發行對象已與公司簽署《附條件生效的股份認購協議》,發行對象以現金方式認購。
此次非公開發行股票的發行價格為27.98元/股,不低於定價基準日前20個交易日公司股票交易均價34.97元/股的80%(定價基準日前20個交易日股票交易均價=定價基準日前20個交易日股票交易總額/定價基準日前20個交易日股票交易總量)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.